Hereditary inclusion body myopathy (HIBM) is a group of neuromuscular disorders characterised by adultonset, slowly progressive distal and proximal muscle weakness and typical muscle pathology. Previously, we have mapped the gene responsible for a recessive form of HIBM to chromosome 9p1 and narrowed the interval to one single YAC clone of 1 Mb in size. As a further step towards the identification of the HIBM gene, we have constructed a detailed physical and transcriptional map of this region. A high resolution BAC contig that includes the HIBM critical region, flanked by marker 327GT4 and D9S1859, was constructed. This contig allowed the precise localisation of 25 genes and ESTs to the proximal region of chromosome 9. The expression pattern of those mapped genes and ESTs was established by Northern blot analysis. In the process of refining the HIBM interval, 13 new polymorphic markers were identified, of which 11 are CA-repeats, and two are single nucleotide polymorphisms. Certainly, this map provides an important integration of physical and transcriptional information corresponding to chromosome 9p12-p13, which is expected to facilitate the cloning and identification not only of the HIBM gene, but also other disease genes which map to this region.
Introduction
Hereditary inclusion body myopathy (HIBM) (OMIM 600737) is a unique group of neuromuscular disorders characterised by adult onset, slowly progressive distal and proximal muscle weakness and a typical muscle pathology including rimmed vacuoles and filamentous inclusions. Subsequently Christodoulou et al 8 have reported the same locus involved in quadriceps sparing HIBM in additional Jewish patients from Persian origin, and in other ethnic groups, and very recently Mirabella et al 9 have described an
Italian family with autosomal recessive quadriceps-sparing inclusion-body myopathy also linked to this locus. Ikeuchi et al 10 have also reported that a distal myopathy with rimmed vacuoles observed in Japanese patients maps to the same locus. This disorder is very similar to HIBM in Persian Jews: onset in early adulthood with drop foot; biopsies show rimmed vacuoles and inclusions of the same nature. The main difference consists in the progression which eventually involves the quadriceps within 10 years of onset, resulting in early loss of ambulation of the Japanese patients. Today it is agreed that very likely these conditions are allelic forms of the same disorder. Many previous studies have shown that the short arm of chromosome 9 and in particular the region 9p12-p13 plays an important role in a large number of common diseases, such as acute lymphoblastic leukaemia, 11 non-Hodgkin's lymphoma, 12 lung cancer, 13 hepatocellular carcinoma (HCC), 14 as well as in rare diseases, such as arthrogryposis multiplex congenita, distal, type 1 (AMCD1), 15 acromesomeric dysplasia (AMDM), 16 cartilage hair hypoplasia (CHH), 17 and also in a form of distal hereditary motor neuropathy (HMN) found in Jerash. 18 At present, the availability of a precise physical map of chromosome 9p12-p13 is very restricted, and very few mapped genes have been identified in this region. Therefore, the construction of a contiguous, high-resolution physical and transcriptional map in this defined genomic interval will certainly contribute to the positional cloning of various disease causing genes. In our attempt to identify the HIBM gene, we have established a complete BAC contig of the chromosomal region 9p12-p13, across the b-tropomyosin gene and the 3' end of the PAX5 gene. This contig has allowed the high resolution physical and transcriptional mapping of several genes, expressed sequence tags, and various additional markers in the region. We have precisely positioned 25 transcripts and analysed their expression pattern. Thirteen new polymorphic sites were identified in this study and fine recombination analysis with these markers allowed the restriction of the HIBM critical region between markers 327GT4 and D9S1859, an interval of about 700 kb. Among the genes and ESTs located between these flanking markers, 12 prevail as potential candidate genes for HIBM.
Materials and methods
Construction of a high resolution BAC contig BAC clones were identified by PCR screening of human BAC libraries (Down to the well 2 ± GenomeSystems Inc; CITB library, Release IV ± Research Genetics Inc), according to the manufacturers' instructions, or from the released data of the Sanger Center (RPCI-11 library ± BACPAC Resources). BAC DNA from single clones was prepared using the QIAGEN Plasmid Maxi kit. The BAC DNA ends were directly sequenced using primers T7 and Sp6, on an ABI Prism 377 automated sequencer. All end sequences were analysed for repetitive elements using the RepeatMasker web server, and subsequently used as STS to screen the BAC libraries again. This process was repeated until a complete BAC contig was established. To confirm the precision of the contig constructed, the content of each clone in the contig was assessed twice by high stringent hybridisation of known markers and by 40 novel STS markers derived from the BACs ends.
Identification of novel polymorphic markers BAC clones were partially restricted with Sau3A (Boehringer Mannheim) and shotgun cloned into BamHI linearised pSPL3 vector (Gibco-BRL). Plated colonies were transfered to nylon membranes (OSMONICS) and hybridised with a Poly(dA-dC)´Poly(dG-dT) probe (Amersham-Pharmacia Biotech). Plasmid inserts from positive colonies were sequenced and PCR amplification primers flanking the repeated region were designed. By searching the Sanger Center recently released BAC sequences, we have been able to identify additional repeat sequences. These sequence data were produced by the Human Chromosome 9 Sequencing Group at the Sanger Center and can be obtained from ftp:// ftp.sanger.ac.uk/pub/human/sequences/Chr_9/. Each marker was tested on several unrelated individuals to determine its polymorphic status. Genotyping with the newly identified markers was performed using amplification with radioactive labelled PCR primers, and denaturing polyacrylamide gel electrophoresis as previously described. 4 
Transcript map
All genes and ESTs previously mapped to the region between D9S163 and D9S50 were selected for further localisation based on the following maps and databases: The human transcript map 19 All the selected ESTs were precisely mapped within the HIBM contig by high stringency hybridisation. In addition, all new genomic sequences derived from the BAC clone insert ends and the shotgun sequences were systematically compared with EST databases using the BLASTN 2.0 software. 20 Sequences found to match additional ESTs were also tested against the BAC contig by PCR amplification and hybridisation. The resulting integrated map is shown in Figure 1 . Washington.edu/cgi_bin/Repeat Masker.
Northern blot analysis

Pulsed-field gel electrophoresis
NotI (New England Biolabs, Inc.) digested BAC DNAs were subjected to 1% agarose gels (Seakem, FMC BioProducts), and separated by pulsed-field gel electrophoresis with a CHEF DR-II system(BioRad), in 0.5% TBE at 148C for 16 h, 6.0 V/cm, with an initial and final switch time of 30 s. Following electrophoresis, the gel was stained with ethidium bromide for visualisation of the digested fragments.
Results
Construction of BAC contig
As a further resource for cloning the HIBM disease gene, a genomic BAC contig flanked by the b-tropomyosin gene and the PAX5 gene, encompassing the HIBM critical region, in the chromosome 9p12-p13 region, was generated. BAC libraries were initially screened using three anchor markers D9S1804, D9S1791 and D9S50. Ten BAC clones were identified as positive for these markers ( Figure 1 ). The end sequences of the identified clones were determined by direct sequencing of BAC DNA using primers T7 and Sp6, complementary to the BAC vector sequence. The end sequences were used to develop STS markers for screening BAC libraries again. This process was repeated until all gaps were closed and a complete BAC contig was achieved ( Figure  1 ). Overlap between clones was identified by amplification 89CA is a polymorphic marker described by Vakkilainen et al. 34 Non polymorphic microsatellites are not shown. The precise location of BAC559O12, BAC100H11, BAC514K23 and BAC444N18 ends was not tested. The internal order in the underlined clusters is not definitive. Note that the map is not to scale.
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Four clones from the RPCI-11 library ± BAC112J3; BAC327L3; BAC113A10; BAC421H8 ± were mapped in this locus by the Sanger Center; we confirmed their location in this contig by hybridization with the relevant markers as illustrated in Figure 1 . A total of 23 BAC clones were identified, (four from the RPCI-11 library, as mentioned above, and 19 by library screening: nine from Genome Systems ± BAC107C13; BAC3L23; BAC91N8; BAC104I10; BAC27I1; BAC146F24; BAC199A5; BAC25J5; BAC108F12, and the remaining 10 from Research Genetics) and 40 novel sequence tagged sites markers were developed from the end sequences of these BAC clones (Figure 1 ; primer sequences are available upon request). These STS were used to construct a high resolution physical map for the region from b tropomyosin gene to the 3' end of PAX5 gene (WI-7677) (Figure 1) , creating a tiling path of the candidate interval. The sizes of inserts were determined by PFGE after NotI digestion, and according to sequence data. The size of the contig was estimated based on the sizes of individual clones and potential overlap between clones.
Identification of novel polymorphic markers
In the process of constructing this detailed physical map we have identified several new polymorphic markers within the established contig. Eleven novel microsatellites and two single nucleotide polymorphisms were detected ( Table 2 ). All repeat markers except 444CA, 327GT6 and 327CA3, were found to be polymorphic in the studied populations. Markers 444CA and 27CA were derived from the Sp6 end sequences of BAC444N18 and 27I1, respectively. 570CA was identified through sequencing a random plasmid subclone derived from BAC570K22, and 47CA31 and 47CA8 were identified in BAC47N15 by hybridisation with a Poly(dA-dC)´Poly(dG-dT) probe, as described in Materials and methods. All the remaining repeats (113GT2, 327GT6, 327GT4, 327CA1, 327GT5) were defined from the published sequences of BACs 113A10 and 327L3 (Accession numbers, AL138834 and AL135841).
The precise location of these markers was determined by STS content mapping in all BAC clones within the contig (Figure 1 ). Additionally, two single nucleotide polymorphisms were found in BAC257I6. 257Sp6 C/T polymorphism was found in the sequence derived from the Sp6 end of BAC 257I6 and the second polymorphism, a base substitution C to A, was identified while sequencing a subclone of BAC257I6. Both polymorphisms were found to create a restriction site for MseI (T'TAA).
Transcript map
In an attempt to obtain a more complete transcription map of the genomic contig generated, we searched several databases for ESTs and genes that potentially map to chromosome 9p12-p13, between the b-tropomyosin gene and marker D9S50. More than 50 transcripts were selected for this fine mapping study.
Twenty-five different transcripts were unambiguously positioned and ordered in the transcription map we constructed. Most of those were hybridised on MTN blots, GCT GAC GTA G  TTA CAC AGA GAC CAG CAG GC  115  stSG26337  GCC GAA TGA TAC AGC CCT TA  AAA GAA GGA GCT GTC CTG AGG  138  SHGC-10717  GGA GCA GAA ATT GCC AAC AT  GGG TGG AAG GGG ATA GGT AA  116  SHGC-33250  TAC AAT TAG GAG CAA GTA AGA AGC G  TAC ACC AGG AAC TGA AAT ATC ACT G  133  WI-14287  ATC ATT TTT ATT GGA GCA TGA CC  GTT CCA GCC AGT CCC CAC  132  stSG1907  TTG TAC CCA TGT GTC TGT CAC  GGG TGA CCT AGG CAG CAT TA  131  stSG2215  GTG ATG AAA ATC TCA GGG AAG G  CTC TGA AGT GGG AGA CGG AG  183  stSG2362  AGG CAC AGA CAT TCC CAA AC  CTG GAA GCT GCA GTC TAC ACC  147  stSG62716  AGT CCC AGC TCC ATC CAT C  CAG CAT CTT TCC AGA GGA GG  159  A003M47  GAA CAG GAA TAA AGA AAT CTG  GAT TCA TCC AAG CTT AAA  124  T78312 CCT Physical Table 3 shows a summary of all the expression data accumulated for those ESTs both from database information and from our Northern blotting results (all ESTs were assayed by Northern blot except stSG55665, stSG26337, stSG2362, stSG62716, stSG52289, T83948 and WI-7677). Figure 1 indicates the precise location of these transcripts in the genomic contig.
Among those, 17 transcripts are ESTs expressed in various tissues, with low or no homology to known genes, while the remaining eight are ESTs derived from genes with known function.
b-tropomyosin (TPM2), an abundant skeletal muscle protein of 284aa, 21 Refinement of the HIBM candidate region Previously we restricted the HIBM disease interval between D9S1791 and D9S50, based on recombination events and linkage disequilibrium. 7 The distal boundary, D9S1791, was defined by a recombination event observed in unaffected individual F34 II-5. 7 However, very recently, the clinical status of this individual has dramatically changed from unaffected to affected, and therefore his haplotype does not reflect a recombination event, but rather his affected status. Based on these results, D9S1791 cannot be considered as the distal boundary of the HIBM interval. Moreover, haplotype analysis in other families with additional markers allowed us to relocate the HIBM candidate interval between 327GT4 on the telomeric side, and D9S1859 on the centromeric side, based on recombination events observed in affected individuals solely (Figure 2 ): the recombinant chromosome found in affected individual F10 III-4 defined the distal boundary as 327GT4 and the recombination event observed in individual F5 III-4 placed the proximal boundary as marker D9S1859. Based on the newly established BAC contig, we conclude that the HIBM critical interval, between markers 327GT4 and D9S1859 covers a region of approximately 700 kb of DNA.
Current positional candidates
The BAC physical map allowed us to verify and refine the location of 25 genes and ESTs mapping to chromosome 9p12-p13 (Table 3, Figure 1 ). As a result we have been able to exclude a large number of genes and ESTs as potential HIBM candidate genes. PAX5 and b-tropomyosin were already excluded in our previous study, 7 stSG2215, CREB3, SHGC-33250, TLN, A003M47, T78312, stSG26337, stSG55665, stSG2362 and stSG62716 were excluded based on the recombination observed with 327GT4. KIAA0175 transcript was excluded due to recombination event with D9S1859. The 12 remaining transcripts (Table 3 ) located between these two flanking markers can be considered as candidate disease causing genes in HIBM. Among those, eight are ESTs with no similarity to any known gene, and four (ST15, CCIN, CLTA and GNE) are genes with a known function. CCIN is expressed only in testing. The other three genes are expressed in a variety of tissues, including skeletal muscle, the affected tissue in HIBM. Clathrin light chain A (CLTA) is a regulatory element 327L3  CAG ATG AAC TTA TTC CAG G  CTA CCT AGT GCT ATT ACT AG  118  327GT4  327L3  TAT GTC TTC ATT TGG GTG  CTC ATA ACC TAG TTC TCT GC  152  327GT5  327L3  TGA CTT CAC AGC TGC CTC CTC A  GTT ACA CAG TTC CAT GCT GAC  134  113GT2  113A10  GTT CTT GAG AGA AAC AGT AC  CTT GTC AGC CTC CAT AAT CAG  120  47CA8  47N15  CCT GAT GGT TAA TGA TGT CAA GC  GTG GCT TGT ATC TAT AGT CC  220  47CA31  47N15  CCT TAT AGA ACC TGT GTG AG  GGA TGT GAT CAG AAA ATT CC  215  27CA  27I1  CAC TCC AGC TGG TGC AAC AG  AGC CAC TTG GTC CTT GAG GG  120  570CA  570K22  GGA CAC ACA GCC ACT CAG  GCA AAC TGA GGA GTA CTC  124  Single nucleotide in clathrin gene function known to be involved in several pathways of lysosomal proteolysis, in various cell types. Clathrin has also been implicated in the pathology of Alzheimer's disease and Pick's disease. Immunohistochemical stainings of muscle fibre from Japanese HIBM patients did not lead to definitive conclusions about differential expression of this protein between those and control muscle tissue. 32 According to these data, the involvement of CLTA in HIBM cannot be ruled out at this point. The involvement of the three known additional genes located in the interval in the pathogenesis of HIBM seems less likely: mutations in the bifunctional enzyme GNE have been related to sialuria, a rare inborn error of metabolism characterised by cytoplasmic accumulation and increased urinary excretion of free neuraminic acid; ST15 has been recently recognized as a matrix protein regulated tumour Although none of those four genes has been directly involved in any known muscle function, their potential relevance or irrelevance to HIBM has still to be established.
Discussion
The positional cloning approach still represents a very potent tool for the identification of a disease gene of unknown biological or biochemical function. The first step towards the identification of genes located in a specific chromosomal fragment is the construction of a high resolution genomic map within this region.
Our previous studies localised the HIBM gene into a region of chromosome 9p12-p13 flanked by markers D9S1791 and D9S50 in a 1 Mb interval laying on a single YAC. 7, 33 BAC end walking was used for the construction of a contig covering the relevant region. Analysis of single BAC libraries revealed the presence of gaps at different locations in the region. Only by screening three different BAC genomic libraries, we were able to establish a complete contig spanning the genes b tropomyosin and the 3' end of PAX5, which includes the HIBM candidate region. This continuous contig was used as the basis for the generation of a highly detailed physical and transcriptional map of the region. We have precisely ordered 40 different loci , and identified 13 new polymorphic markers which allowed the refinement of the haplotype analysis in HIBM families. Although four of the clusters could not be definitely ordered internally by BAC hybridisation, we have established their location from combined hybridisation results and data of all available databases relating to them (GeneMap99, The Sanger Center, GDB). Our previous genotyping studies with eight polymorphic markers located the HIBM disease in the interval flanked by D9S1791 and D9S50, based on both recombination and linkage disequilibrium data. The disease status in each subject was determined by personal clinical examination of one of us (Z Argov and M Sadeh). Unfortunately, there are no known pre-symptomatic tests in HIBM to predict the status of a`currently healthy' Figure 2 Haplotype analysis in two HIBM families showing recombination events in the vicinity of the HIBM locus. Haplotypes comprise alleles at the listed loci ordered telomeric to centromeric W1226, D9S165, D9S1878, D9S163, 327GT4, D9S1804, 89CA, D9S1791, 27CA, D9S1859, 570CA, D9S50 and D9S887, (n=not tested). Individuals are designated with generation and pedigree numbers. Disease status is indicated: affected, filled symbols; unaffected, clear symbols. Deceased individuals are denoted by slashes.
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Physical and transcriptional map of IBM2 locus I Eisenberg et alindividual (like the markedly elevated serum creatine kinase before onset of muscle weakness in various muscular dystrophies). Since all of the patients in the HIBM families analysed were diagnosed before age 35 years, unaffected family members below the age of 35 years were excluded from analysis in our studies. The recombination event which located the distal boundary at D9S1791 was recognised in an unaffected individual which was examined at age 43 years and showed no sign of muscle disease then. Since in this family the age of onset was 33 years, that is 10 years before, the data observed pointed to a recombination event.
However, a recent reexamination of the patient revealed the clinical criteria for HIBM diagnosis, so that we are now aware that some of the presently healthy members of the families studied may become symptomatic at a later time. Therefore only recombination events observed in affected individuals are taken into consideration. At present, we cannot consider D9S1791 as the distal boundary defining the HIBM interval; the closest unambiguous recombination event has been recognised at marker 327GT4 in an affected individual. Twenty-five genes and ESTs derived from all screened databases have been analysed for their precise location in the 9p12-p13 region, and for their expression pattern in a variety of tissues. Our results show that most of those transcripts are present in more than one tissue type, some are more specific to certain types, such as foetal liver or spleen, brain or testis. Furthermore no transcript was found to be expressed solely in skeletal muscle tissue. Among the 25 transcripts identified in the region, two cytoskeletal proteins, b-tropomyosin and talin, are the only genes with a recognised function in muscle, and therefore they were the most attractive genes to be potentially involved in HIBM. Both genes were subsequently excluded by position, by linkage disequilibrium data 7 and, for talin, because a recombination event has been recognised with a polymorphic site within the gene 24 in one affected individual.
However, the function of many of the genes and ESTs mapped to 9p12-p13 has not yet been established, and the continuous flow of sequence and transcriptional data demands a constant update of our analysis, till the systematic sequencing of the entire interval is completed. Our goal is the identification of all the genes in human chromosome 9p12-p13, including the HIBM interval laying at present between 327TG4 and D9S1859. The high resolution physical and transcriptional map established in these studies will contribute to the positional cloning of various disease causing genes located in this region, among them the gene responsible for HIBM. Certainly the identification of the gene will have immediate implications such as efficient genetic counseling for HIBM families, and precise knowledge of all HIBM allelic disorders. Moreover, further characterisation of the HIBM causing gene will provide important insights into the mechanisms of inclusion body myopathies and increase our understanding of the molecular basis for impaired function of the muscle tissue.
